argenx SE (ARGX.BR)
EUR 523.0
(-1.54%)
EUR 523.0
(-1.54%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 925.49 Million EUR | 142.71% |
| 2022 | 381.31 Million USD | 3086.52% |
| 2021 | -12.76 Million USD | 95.07% |
| 2020 | -258.8 Million EUR | -118.13% |
| 2019 | -118.64 Million EUR | -582.83% |
| 2018 | 24.57 Million EUR | -43.75% |
| 2017 | 43.68 Million EUR | 182.33% |
| 2016 | 15.47 Million EUR | 106.49% |
| 2015 | 7.49 Million EUR | 64.07% |
| 2014 | 4.56 Million EUR | 70.61% |
| 2013 | 2.67 Million EUR | 22.6% |
| 2012 | 2.18 Million EUR | 49.75% |
| 2011 | 1.45 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 425.25 Million EUR | 130.53% |
| 2024 Q1 | 357.82 Million USD | 35.33% |
| 2023 Q3 | 293.79 Million USD | 19.17% |
| 2023 Q1 | 200.8 Million USD | 24.43% |
| 2023 Q2 | 246.52 Million USD | 22.77% |
| 2023 FY | 925.49 Million EUR | 142.71% |
| 2023 Q4 | 367.36 Million USD | 25.04% |
| 2022 FY | 381.31 Million USD | 3086.52% |
| 2022 Q3 | 127.71 Million USD | 81.97% |
| 2022 Q4 | 161.37 Million USD | 26.35% |
| 2022 Q1 | 22.04 Million USD | -15.3% |
| 2022 Q2 | 70.18 Million USD | 218.44% |
| 2021 Q1 | 158.15 Million EUR | 1026.7% |
| 2021 FY | -12.76 Million USD | 95.07% |
| 2021 Q2 | 312.24 Million USD | 97.43% |
| 2021 Q3 | 857 Thousand USD | -99.73% |
| 2021 Q4 | 26.02 Million USD | 2936.41% |
| 2020 Q4 | 14.03 Million EUR | 0.0% |
| 2020 FY | -258.8 Million EUR | -118.13% |
| 2020 Q2 | 22.38 Million EUR | 0.0% |
| 2019 Q1 | 40.93 Million EUR | 2779.29% |
| 2019 FY | -118.64 Million EUR | -582.83% |
| 2019 Q4 | 20.98 Million EUR | 173.03% |
| 2019 Q3 | 7.68 Million EUR | -10.19% |
| 2019 Q2 | 8.55 Million EUR | -79.09% |
| 2018 Q2 | 13.84 Million EUR | 101.54% |
| 2018 Q3 | 2.44 Million EUR | -82.34% |
| 2018 FY | 24.57 Million EUR | -43.75% |
| 2018 Q1 | 6.86 Million EUR | -33.43% |
| 2018 Q4 | 1.42 Million EUR | -41.83% |
| 2017 Q1 | 7.11 Million EUR | 93.52% |
| 2017 Q2 | 18.56 Million EUR | 160.87% |
| 2017 Q4 | 10.31 Million EUR | 34.09% |
| 2017 Q3 | 7.69 Million EUR | -58.56% |
| 2017 FY | 43.68 Million EUR | 182.33% |
| 2016 Q3 | 5.5 Million EUR | 45.64% |
| 2016 Q1 | 2.51 Million EUR | 32.96% |
| 2016 FY | 15.47 Million EUR | 106.49% |
| 2016 Q2 | 3.77 Million EUR | 50.51% |
| 2016 Q4 | 3.67 Million EUR | -33.21% |
| 2015 Q2 | 1.72 Million EUR | 31.8% |
| 2015 FY | 7.49 Million EUR | 64.07% |
| 2015 Q4 | 1.88 Million EUR | -26.43% |
| 2015 Q3 | 2.56 Million EUR | 48.66% |
| 2015 Q1 | 1.31 Million EUR | -26.42% |
| 2014 Q2 | 308.66 Thousand EUR | -9.48% |
| 2014 Q3 | 2 Million EUR | 550.83% |
| 2014 Q4 | 1.78 Million EUR | -11.35% |
| 2014 FY | 4.56 Million EUR | 70.61% |
| 2014 Q1 | 341 Thousand EUR | -63.5% |
| 2013 Q2 | 530.61 Thousand EUR | 21.42% |
| 2013 Q3 | 1.67 Million EUR | 215.1% |
| 2013 Q4 | 934.37 Thousand EUR | -44.12% |
| 2013 Q1 | 437 Thousand EUR | 0.0% |
| 2013 FY | 2.67 Million EUR | 22.6% |
| 2012 FY | 2.18 Million EUR | 49.75% |
| 2011 FY | 1.45 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -149656.759% |
| ABIVAX Société Anonyme | 3.91 Million EUR | -23545.804% |
| Adocia SA | 1.38 Million EUR | -66722.872% |
| Aelis Farma SA | 12.35 Million EUR | -7389.05% |
| Biophytis S.A. | -803 Thousand EUR | 115354.891% |
| Advicenne S.A. | 1.42 Million EUR | -64801.597% |
| genOway Société anonyme | 20.1 Million EUR | -4504.374% |
| IntegraGen SA | 5.01 Million EUR | -18342.51% |
| Medesis Pharma S.A. | -2.66 Million EUR | 34830.857% |
| Neovacs S.A. | 29.31 Thousand EUR | -3157083.499% |
| NFL Biosciences SA | -56.06 Thousand EUR | 1650886.193% |
| Plant Advanced Technologies SA | 2.15 Million EUR | -42888.038% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 65308.479% |
| Sensorion SA | 3.78 Million EUR | -24333.223% |
| Theranexus Société Anonyme | -4.63 Million EUR | 20051.684% |
| TME Pharma N.V. | -127 Thousand EUR | 728837.615% |
| Valbiotis SA | 2.66 Million EUR | -34588.785% |
| TheraVet SA | -530.79 Thousand EUR | 174460.163% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -72946.312% |
| BioSenic S.A. | 543 Thousand EUR | -170341.394% |
| Celyad Oncology SA | 33 Thousand EUR | -2804435.67% |
| DBV Technologies S.A. | 4.15 Million EUR | -22149.701% |
| Galapagos NV | 203.73 Million EUR | -354.265% |
| Genfit S.A. | 28.22 Million EUR | -3179.113% |
| GeNeuro SA | -293.8 Thousand EUR | 315109.112% |
| Hyloris Pharmaceuticals SA | 1.99 Million EUR | -46314.081% |
| Innate Pharma S.A. | -4.12 Million EUR | 22558.063% |
| Inventiva S.A. | 17.5 Million EUR | -5188.553% |
| MaaT Pharma SA | 1.65 Million EUR | -55821.255% |
| MedinCell S.A. | 9.28 Million EUR | -9864.436% |
| Nanobiotix S.A. | 36.2 Million EUR | -2456.056% |
| Onward Medical N.V. | -14.81 Million EUR | 6345.76% |
| Oryzon Genomics S.A. | 13.94 Million EUR | -6535.378% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -41458.005% |
| Oxurion NV | 104 Thousand EUR | -889800.741% |
| Pharming Group N.V. | 220.1 Million EUR | -320.482% |
| Poxel S.A. | 1000.00 EUR | -92549577.1% |
| GenSight Biologics S.A. | 3 Million EUR | -30749.892% |
| Transgene SA | -28.4 Million EUR | 3358.333% |
| Financière de Tubize SA | -2.02 Million EUR | 45700.296% |
| UCB SA | 3.34 Billion EUR | 72.307% |
| Valneva SE | 52.83 Million EUR | -1651.607% |
| Vivoryon Therapeutics N.V. | -3.09 Million EUR | 30002.965% |